Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol Myers (BMY) wins EC approval for Zeposia for a second indication ??? ulcerative colitis.

Bristol Myers (BMY) Zeposia Gets EC Nod for Ulcerative Colitis

AstraZeneca

CVS Health

Novartis

Patterson Companies

Needless to say, 2021 has been a banner year for equities, with the S&P 500 up a stunning 25%.

Top Strategist Says Health Care Could Rule in 2022: 5 Dividend Winners

The European Commission has approved Bristol Myers Squibb & Co's (NYSE: BMY) Zeposia (ozanimod) for ulcerative colitis (UC). The approval comes for adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Bristol Myers' Zeposia Wins European Approval For Ulcerative Colitis

Bristol Myers Squibb's stock has significantly underperformed the market in recent months due to expiring patents. The market seems to be ignoring the excellent pipeline progress that has occurred as part of the company's acquisitions of Celgene and MyoKardia.

Bristol Myers Squibb: Great Value And Great Pipeline, But Exaggerated Fears

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis

Bristol Myers (BMY) announces extension of FDA review of its cardiovascular drug mavacamten. The new target action date is Apr 28, 2022.

Bristol Myers' (BMY) Cardiovascular Drug Review Extended by FDA

Value investors can take advantage of the huge discrepancy between the company's valuation and its fundamentals.

Why Bristol Myers Squibb Is a Table-Pounding Buy

Bristol Myers Squibb is the pharma with the share price that refuses to budge. Over the past five years, shares are up just 2%.

Bristol Myers Squibb: 5 Reasons To Buy The Current Dip, And 1 Caveat

Bristol Myers Squibb & Co (NYSE: BMY) has announced that the FDA has extended the decision date for mavacamten. Bristol Myers announced that the date has slid from January 28, 2022, to April 28, 2022.

Bristol Myers' Mavacamten Added Via $13B Myokardia Buyout, Hit By FDA Delay

Amgen

These two drugmakers have a solid track record.

2 Dividend Stocks to Buy Right Now

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--Bristol Myers Squibb Announces New PDUFA Date for Mavacamten

Bristol Myers Squibb Announces New PDUFA Date for Mavacamten

GlaxoSmithKline

Eli Lilly

Pfizer

Of the top nine members of Big Pharma with high dividend yields, Eli Lilly and Co. ( LLY , Financial) brings up the rear at 1.32%. But that hardly tells the full story.

Look to Big Pharma for Healthy Dividends

Chevron

Johnson & Johnson

Kraft Heinz

Coca-Cola

Mastercard

Mondelez

Procter & Gamble

Royalty Pharma

Sirius XM Holdings Inc

STORE Capital

U.S. Bancorp

Visa

Verizon

This Buffett holdings list from Kiplinger first appeared 9/16/21 online. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 11/16/21 YCharts data. 28 of 43 current Berkshire Hathaway-owned stocks pay dividends. As of 11/16/21 the top-ten ranged 2.36%-4.92% by annual yield and ranged 18.73%-87.33% per broker-estimated price-target-upsides.

3 Ideal Dogs Delight Buffett's November Dividend Holdings

AbbVie

Merck

Warren Buffett's Berkshire Hathaway Inc (NYSE: BRK-A) cleared its stake in Merck & Co Inc (NYSE: MRK) in Q3, right on the eve of a significant stock price boost thanks to the Phase 3 success of its Ridgeback Biotherapeutics-partnered COVID-19 pill molnupiravir. The molnupiravir data sent Merck's share price from about $75 apiece the previous day to as high as about $84.

Berkshire Exited Merck Before COVID Pill Boost; Trimmed Holdings In AbbVie, Bristol Myers In Q3

Gilead Sciences

Walgreens

For years, one of the most dependable sectors, especially for more conservative investors, was health care, which includes the top pharmaceutical and biotech stocks.

Health Care Stocks Cheapest in 30 Years: 5 With Big Dividends to Buy Now

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs

Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs

Celgene

NEW ORLEANS, Nov. 17, 2021 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 6, 2021 to file lead plaintiff applications in a securities class action lawsuit against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE: BMY), if they received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS' acquisition of Celgene on November 20, 2019.  This action is pending in the United States District Court for the Southern District of New York.

BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY

Currently, there are many indicators showing that the U.S. stock market is overvalued.

3 Big Pharma Stocks Trading Near 52-Week Lows

Floor & Decor Holdings

Marsh & McLennan

Organon & Co

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) published its third-quarter 13F filing earlier this week, reporting U.S. equity position changes during the three months to the end of September.

Buffett Continues to Sell Stock as Turnover Increases

Charter Communications

Liberty Global Ltd

Liberty Media Corp-Liberty SiriusXM

Berkshire Hathaway CEO Warren Buffett kept up his bearish streak in Q3 2021, but he did add a pair of positions from two of his favored industries.

10 Stocks Warren Buffett Is Selling (And 4 He's Buying)

Warren Buffett's Berkshire Hathaway Inc said on Monday it eliminated its investment in Merck & Co and reduced its stakes in Abbvie Inc and Bristol-Myers Squibb Co, as it pared its overall stock market investments.

Buffett's Berkshire cuts stakes in U.S. drugmakers, invests in drug royalty company

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AHA--Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across Wide Range of Doses

Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses

Lockheed Martin

Buying above-average companies at below-average prices is a winning strategy.

2 Blue Chip Dividends Getting Way Too Cheap

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CoulditbeHCM--BMS Launches Could It Be HCM? Campaign to Increase Awareness of Hypertrophic Cardiomyopathy (HCM), the Most Common Inherited Heart Disease

Bristol Myers Squibb Launches Could It Be HCM? Campaign to Increase Awareness of Hypertrophic Cardiomyopathy (HCM), the Most Common Inherited Heart Disease

Bristol Myers Squibb & Co (NYSE: BMY) has announced long-term data from a mavacamten study acquired via a $13 billion MyoKardia buyout.  Heart patients who received mavacamten in a cohort of the long-term MAVA-LTE study saw significant reductions in median levels of a hormone called NT-proBNP (58% at week 24 and 67% at week 48).

News for Bristol-Myers Stock (BMY)